ConductScience.org, home

Paper41226558

Acalabrutinib May Offer a New Therapeutic Approach for Consolidation and Maintenance of Primary CNS Lymphoma with Expression of MYD88 and CD79B Gene Variants: A Case Report and Literature Review of Primary CNS Lymphoma in the BTKi Era.

Allison E and 3 others. Int J Mol Sci, 2025. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Acalabrutinib May Offer a New Therapeutic Approach for Consolidation and Maintenance of Primary CNS Lymphoma with Expression of MYD88 and CD79B Gene Variants: A Case Report and Literature Review of Primary CNS Lymphoma in the BTKi Era. Papers, record 41226558. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41226558

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Acalabrutinib May Offer a New Therapeutic Approach for Consolidation and Maintenance of Primary CNS Lymphoma with Expression of MYD88 and CD79B Gene Variants: A Case Report and Literature Review of Primary CNS Lymphoma in the BTKi Era.
PubMed
Journal
Int J Mol Sci
PubMed
Year
2025
PubMed
Publication types
Journal Article, Case Reports, Review
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2025-12-15
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Allison EEleanor
2Campbell AAshleahttps://orcid.org/0000-0002-9909-3723
3Watson AMAnne-Marie
4Beaton BBrendan

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CD79 AntigensMajor topic
Central Nervous System NeoplasmsMajor topic
PyrazinesMajor topic
Myeloid Differentiation Factor 88Major topic
BenzamidesMajor topic
LymphomaMajor topic
Humans
Male
Agammaglobulinaemia Tyrosine Kinase
Middle Aged

Source PubMed

Download CSV of topics

References84

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
139575767Distinct epigenetic and transcriptional profiles of Epstein-Barr virus-positive and negative primary CNS lymphomas.Neuro Oncol2025https://conductscience.org/library/papers/39575767PubMed
234277452Efficacy and Safety of Ibrutinib in Central Nervous System Lymphoma: A PRISMA-Compliant Single-Arm Meta-Analysis.Front Oncol2021https://conductscience.org/library/papers/34277452PubMed
331790142The immune landscape and response to immune checkpoint blockade therapy in lymphoma.Blood2020https://conductscience.org/library/papers/31790142PubMed
438589905Ibrutinib disrupts blood-tumor barrier integrity and prolongs survival in rodent glioma model.Acta Neuropathol Commun2024https://conductscience.org/library/papers/38589905PubMed
534523186Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma.Cancer Sci2021https://conductscience.org/library/papers/34523186PubMed
627132696
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Lancet Haematol2016https://conductscience.org/library/papers/27132696PubMed
737397356CAR-T cells neurotoxicity from consolidated practice in hematological malignancies to fledgling experience in CNS tumors: fill the gap.Front Oncol2023https://conductscience.org/library/papers/37397356PubMed
836465385Bruton's tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review.Front Oncol2022https://conductscience.org/library/papers/36465385PubMed
935004280Preliminary Evaluation of Zanubrutinib-Containing Regimens in DLBCL and the Cerebrospinal Fluid Distribution of Zanubrutinib: A 13-Case Series.Front Oncol2021https://conductscience.org/library/papers/35004280PubMed
1035732829The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.Leukemia2022https://conductscience.org/library/papers/35732829PubMed
1130033836Combination immunotherapy as a non-chemotherapy alternative for refractory or recurrent CNS lymphoma.Leuk Lymphoma2019https://conductscience.org/library/papers/30033836PubMed
1230885253Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis.Acta Neuropathol Commun2019https://conductscience.org/library/papers/30885253PubMed
1319767089High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.Lancet2009https://conductscience.org/library/papers/19767089PubMed
1429054815
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.
Lancet Haematol2017https://conductscience.org/library/papers/29054815PubMed
1535732356Durable remission with Bruton's tyrosine kinase inhibitor therapy in a patient with leptomeningeal disease secondary to relapsed mantle cell lymphoma.BMJ Case Rep2022https://conductscience.org/library/papers/35732356PubMed
1639866943
Central nervous system posttransplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation successfully treated with combination therapy of acalabrutinib and immunochemotherapy: A case report and literature review.
EJHaem2025https://conductscience.org/library/papers/39866943PubMed
1738406527Complete response of mantle cell lymphoma with central nervous system involvement at diagnosis with acalabrutinib - Case report.EJHaem2024https://conductscience.org/library/papers/38406527PubMed
1835116520Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution.Transl Cancer Res2021https://conductscience.org/library/papers/35116520PubMed
1938135609Evidence-based management of primary and secondary CNS lymphoma.Semin Hematol2023https://conductscience.org/library/papers/38135609PubMed
2029476222Ibrutinib brain distribution: a preclinical study.Cancer Chemother Pharmacol2018https://conductscience.org/library/papers/29476222PubMed

See all 84 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42440393Rare CNS manifestation of high-risk CLL with excellent response to triplet targeted therapy.Leuk Res Rep2026https://conductscience.org/library/papers/42440393PubMed
42027642Intravascular large B-cell lymphoma mimicking an orbital mass lesion and bilateral cavernous sinus syndrome: A case report.Oncol Lett2026https://conductscience.org/library/papers/42027642PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
BTK695PubTator's text mininghttps://conductscience.org/library/genes/695NCBI Gene
CD79B974PubTator's text mininghttps://conductscience.org/library/genes/974NCBI Gene
MYD884615PubTator's text mininghttps://conductscience.org/library/genes/4615NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41226558

GET https://conductscience.org/api/papers/v1/41226558/references?page=2